Carried by: SFCE ("French Society for the Fight Against Cancer and Leukaemia in Children and Adolescents")
References:
Clinician(s): B. GEOERGER, G. SCHLEIERMACHER, N. CORRADINI, N. ANDRÉ, M. STRULLU, S. DUCASSOU, A. PETIT
Biologist(s): L. LACROIX, G. PIERRON, P. NAIBO, H. CAVE, H. LAPILLONE
Presentation
Patient (child, adolescent, young adult) with paediatric cancer or leukaemia whose treatment has failed: refractory or relapsed disease, potentially eligible for a clinical trial.
Criteria before considering a discussion in MDM-FMG
- Patient potentially eligible for experimental treatment or clinical trial
- Good performance status and life expectancy > 3 months
- Availability of a frozen tumour sample in the event of relapse/progression:
- either a new sample obtained by biopsy or surgery or bone marrow aspiration
- or ‘archived’ material from a procedure performed optimally within the last 3 months
- Constitutional material (blood or bone marrow at complete remission) available
- Not applicable for certain pathologies (Hodgkin’s disease; not contributive for analysis)
MDM cartography
MDM
Type of the MDM
City of the coordinator
Name, first name, and email of the contact
MDM Oncoped Failure of treatment North
Interregional
Villejuif/Paris
Solid tumors :
Birgit GEOERGER
Birgit.geoerger@gustaveroussy.fr
Gudrun SCHLEIERMACHER
gudrun.schleiermacher@curie.fr
Leukaemias :
Marion STRULLU
Arnaud PETIT
MDM Oncoped Failure of treatment South
Interregional
Lyon, Marseille, Bordeaux
Solid tumors :
Nadege CORRADINI
Nicolas ANDRÉ
Leukaemias :
Stéphane DUCASSOU